FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1851-1854 December 17, 1998 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Dexfenfluramine (Redux) was withdrawn from the market in the United States in 1997 amid speculation that millions who used it could have been harmed.^1,2,3 More recently, mibefradil (Posicor) was withdrawn because of suggestions that it may have serious interactions with other drugs.⁴ Adverse reactions to drugs are an important cause of morbidity and mortality; it has been estimated recently that approximately 100,000 Americans die every year as a result of such adverse reactions,⁵ making them one of the most common causes of death. Independent agencies exist to investigate airline accidents, railroad mishaps, and radiation spills and to make recommendations for . . . [Full Text of this Article]

Address reprint requests to Dr. Wood at Rm. 550 MRB 1, Vanderbilt University Medical Center, Nashville, TN 37232-6602.

References

This article has been cited by other articles:

• Berlin, J. A., Glasser, S. C., Ellenberg, S. S. (2008). Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3. Am. J. Public Health 98: 1366-1371 [Abstract] [Full Text]  
• Furberg, C. D., Levin, A. A., Gross, P. A., Shapiro, R. S., Strom, B. L. (2006). The FDA and drug safety: a proposal for sweeping changes.. Arch Intern Med 166: 1938-1942 [Abstract] [Full Text]  
• Wood, A. J.J. (2006). A Proposal for Radical Changes in the Drug-Approval Process. NEJM 355: 618-623 [Full Text]  
• Ray, W. A., Stein, C. M. (2006). Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board. NEJM 354: 194-201 [Full Text]  
• Bennett, C. L., Nebeker, J. R., Lyons, E. A., Samore, M. H., Feldman, M. D., McKoy, J. M., Carson, K. R., Belknap, S. M., Trifilio, S. M., Schumock, G. T., Yarnold, P. R., Davidson, C. J., Evens, A. M., Kuzel, T. M., Parada, J. P., Cournoyer, D., West, D. P., Sartor, O., Tallman, M. S., Raisch, D. W. (2005). The Research on Adverse Drug Events and Reports (RADAR) Project. JAMA 293: 2131-2140 [Abstract] [Full Text]  
• Roden, D. M. (2005). An Underrecognized Challenge in Evaluating Postmarketing Drug Safety. Circulation 111: 246-248 [Full Text]  
• Solomon, D. H., Avorn, J. (2005). Coxibs, Science, and the Public Trust. Arch Intern Med 165: 158-160 [Full Text]  
• Psaty, B. M., Furberg, C. D., Ray, W. A., Weiss, N. S. (2004). Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis. JAMA 292: 2622-2631 [Abstract] [Full Text]  
• Fontanarosa, P. B., Rennie, D., DeAngelis, C. D. (2004). Postmarketing Surveillance--Lack of Vigilance, Lack of Trust. JAMA 292: 2647-2650 [Full Text]  
• Salmon, D. A., Moulton, L. H., Halsey, N. A. (2004). Enhancing Public Confidence in Vaccines Through Independent Oversight of Postlicensure Vaccine Safety. Am. J. Public Health 94: 947-950 [Abstract] [Full Text]  
• Nebeker, J. R., Barach, P., Samore, M. H. (2004). Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting. ANN INTERN MED 140: 795-801 [Abstract] [Full Text]  
• Karter, A. J., Ahmed, A. T., Liu, J., Moffet, H. H., Parker, M. M., Ferrara, A., Selby, J. V. (2004). Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A Retrospective Cohort Study: Response to Delea et al.. Diabetes Care 27: 850-851 [Full Text]  
• Ladewski, L. A., Belknap, S. M., Nebeker, J. R., Sartor, O., Lyons, E. A., Kuzel, T. C., Tallman, M. S., Raisch, D. W., Auerbach, A. R., Schumock, G. T., Kwaan, H. C., Bennett, C. L. (2003). Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project. JCO 21: 3859-3866 [Abstract] [Full Text]  
• Chan, K. A., Truman, A., Gurwitz, J. H., Hurley, J. S., Martinson, B., Platt, R., Everhart, J. E., Moseley, R. H., Terrault, N., Ackerson, L., Selby, J. V. (2003). A Cohort Study of the Incidence of Serious Acute Liver Injury in Diabetic Patients Treated With Hypoglycemic Agents. Arch Intern Med 163: 728-734 [Abstract] [Full Text]  
• Ross, S. D. (2001). Drug-Related Adverse Events: A Readers' Guide to Assessing Literature Reviews and Meta-analyses. Arch Intern Med 161: 1041-1046 [Full Text]  
• Bodenheimer, T. (2000). Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry. NEJM 342: 1539-1544 [Full Text]  
• Jollis, J. G., Landolfo, C. K., Kisslo, J., Constantine, G. D., Davis, K. D., Ryan, T. (2000). Fenfluramine and Phentermine and Cardiovascular Findings : Effect of Treatment Duration on Prevalence of Valve Abnormalities. Circulation 101: 2071-2077 [Abstract] [Full Text]  
• Wood, A. J. J. (1999). The Safety of New Medicines: The Importance of Asking the Right Questions. JAMA 281: 1753-1754 [Full Text]